Table I.

Frequencies of gB-specific Ab and IFN-γ producing cells in ILN and vaginal tract of immunized mice following HSV vaginal infectiona

RegimensILNVaginal Tract
gB-specific Ab SFC/106 cellsIFN-γ SFC/106 cellsgB-specific Ab SFC/106 cellsIFN-γ SFC/106 cells
IgAIgGIgAIgG
Mucosal immunization
D-D3 ± 318 ± 946 ± 231 ± 21 ± 26 ± 4
D-V85 ± 37114 ± 1656 ± 2726 ± 315 ± 637 ± 12
V-D141 ± 27b,c151 ± 14b,c102 ± 19b,c35 ± 11b,c22 ± 562 ± 12b,c
V-V93 ± 30115 ± 2660 ± 2925 ± 617 ± 343 ± 14
D-X5 ± 611 ± 628 ± 199 ± 3
V-X84 ± 16120 ± 646 ± 1730 ± 620 ± 835 ± 18
Vector1 ± 2NDg18 ± 25ND4 ± 4
Vvtk-7 ± 5ND29 ± 165 ± 4ND12 ± 3
Systemic immunization
D-D36 ± 1454 ± 1449 ± 1718 ± 3ND14 ± 3
D-V53 ± 14e77 ± 17e80 ± 15f8 ± 4eND22 ± 7e
V-D46 ± 1362 ± 849 ± 1316 ± 4ND18 ± 3
V-V31 ± 836 ± 555 ± 1510 ± 3ND9 ± 3
D-X56 ± 648 ± 1142 ± 1010 ± 3ND12 ± 10
V-X40 ± 1076 ± 2561 ± 1318 ± 3ND11 ± 5
VectorNDNDNDNDNDND
Vvtk-NDNDNDNDNDND
  • a BALB/c mice (six per group) were immunized mucosally (i.n.) or systemically (i.m.) with gB DNA (D) or rvacgB (V) and boosted 10 days later via the same route used for priming with the alternative vaccine type. Control mice were given vector plasmid DNA or 107 PFU of vvtk-. Eight weeks following boosting, the mice were challenged vaginally with 106 PFU of HSV-1 McKrae. Four days later, the ILN and the vaginal tract were collected from each group. The frequencies of gB-specific Ab and IFN-γ-producing cells were determined by ELISPOT assay. SD is based on the number of SFC from quadruplicates per group.

  • b p < 0.05 compared with gB DNA mucosal priming-rvacgB mucosal boosting or rvacgB mucosal priming-rvacgB mucosal boosting.

  • c p < 0.05 compared with gB DNA systemic priming-rvacGb systemic boosting.

  • d p = 0.08 compared with gB DNA systemic priming-rvacgB systemic boosting.

  • e p < 0.05 compared with rvacgB systemic priming-gB DNA systemic boosting.

  • f p = 0.0002 compared with rvacgB systemic priming-gB DNA systemic boosting.

  • g ND, Not done.